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Abstract
Bacillus subtilis spores have received growing attention regarding potential biotechnological applications, including the use
as probiotics and in vaccine formulations. B. subtilis spores have also been shown to behave as particulate vaccine
adjuvants, promoting the increase of antibody responses after co-administration with antigens either admixed or adsorbed
on the spore surface. In this study, we further evaluated the immune modulatory properties of B. subtilis spores using a
recombinant HIV gag p24 protein as a model antigen. The adjuvant effects of B. subtilis spores were not affected by the
genetic background of the mouse lineage and did not induce significant inflammatory or deleterious effects after parenteral
administration. Our results demonstrated that co-administration, but not adsorption to the spore surface, enhanced the
immunogenicity of that target antigen after subcutaneous administration to BALB/c and C57BL/6 mice. Spores promoted
activation of antigen presenting cells as demonstrated by the upregulation of MHC and CD40 molecules and enhanced
secretion of pro-inflammatory cytokines by murine dendritic cells. In addition, in vivo studies indicated a direct role of the
innate immunity on the immunomodulatory properties of B. subtilis spores, as demonstrated by the lack of adjuvant effects
on MyD88 and TLR2 knockout mouse strains.
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Introduction
Adjuvants are compounds that enhance the potency, quality or
longevity of specific immune responses. The purpose of adding an
adjuvant to a vaccine formulation is to enhance the immunoge-
nicity of the co-administered antigens, reduce the number of doses
required for protective immunity and improve the efficacy of
vaccines in poor responder populations [1,2]. In general, adjuvants
can be classified as delivery systems, immunopotentiators or a
combination of both. Delivery systems, such as mineral salts,
emulsions and liposomes, efficiently present the antigens to the
immune system by aggregating and controlling antigen release.
Immunopotentiators, such as cytokines, saponins and Toll-like
receptor agonists, increase the immune response to antigens by
stimulating the innate immune cells directly [3–5]. These
adjuvants boost immunity by activating antigen-presenting cells
(APCs), which increase the expression of MHC I and/or II
molecules, cytokines and the co-stimulatory molecules that are
required for T-cell contact and activation. APC maturation
determines the magnitude and the type of the T and B cell
responses [6].
The identification and development of new adjuvants is a
priority since the currently licensed adjuvants for human use do
not always induce a potent immune response against different
target pathogens, especially in immunologically hyporesponsive
populations [4]. Modern adjuvants should induce a strong and
balanced immune response with reduced reactogenicity. Further-
more, a good adjuvant should preferentially have a long shelf life
and a low production cost [5].
Previous studies have demonstrated that Bacillus subtilis spores
show a significant adjuvant effect leading to enhanced antibody
responses to either co-administered antigens or antigens that are
adsorbed on the spore surface [7–9]. B. subtilis is a gram-positive
nonpathogenic and endospore-forming bacterium species that has
been used as a tool for different biotechnological applications, such
as probiotic formulations for both humans and animals, expression
systems for heterologous protein production and vaccine vehicles
for the mucosal delivery of antigens [10,11,12]. B. subtilis can be
genetically engineered to express heterologous antigens soon after
spore germination or be presented at the spore surface as fusions
with spore coat proteins [13,14]. B. subtilis endospores offers
unique resistance properties and can survive for long periods of
time under a range of stress conditions, such as high temperature,
desiccation, absence of nutrients and exposure to chemical
solvents. These features facilitate the storage and transport of
these endospores [15].
In this study, we evaluated additional details of the immuno-
logical mechanisms leading to the adjuvant properties of B. subtilis
spores. For that purpose, we used the capsid protein gag p24 from
HIV-1 (Human Immunodeficiency Virus type 1) as a target
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antigen. Gag p24 is an immunodominant protein which plays an
important role in inducing protective immunity to HIV-1;
therefore, it has become an integral component of many vaccine
strategies [16,17]. We investigated whether live or heat-killed B.
subtilis spores can equally promote specific antibody and cell
mediated immune responses to co-administered gag p24 in
different mouse models that are immunized via the subcutaneous
route. Our findings indicate that the adjuvant effects of B. subtilis
spores are not affected by the genetic background of the host
lineage and require the involvement of the innate immune system
for proper stimulation of adaptive immune responses.
Materials and Methods
Ethics Statement
All procedures and experiments involving mice were performed
with prior approval by the committee on the ethical use of
laboratory animals from the Institute of Biomedical Sciences of the
University of Sa˜o Paulo (Protocol #045) and in accordance with
the recommendations in the guidelines for the care and use of
laboratory animals of the National Committee on the Ethics of
Research (CONEP).
Bacterial strains and spore preparation
The B. subtilis WW02 strain (leuA8 metB5 trpC2 hsdRM1
amyE::neo) was kindly provided by Dr. Wolfgang Schumann from
University of Bayreuth, Germany. B. subtilis WW02 is a widely
used strain, which is a derivative from B. subtilis 1012, a reference
laboratory strain with a sequenced genome and known physio-
logical features [18,19]. Spores were prepared from this strain, as
previously described [20]. Briefly, sporulation of B. subtilis was
induced following cultivation in F medium for 72 h at 37uC. The
culture was centrifuged, and the pellet was suspended in 50 mM
Tris-HCl (pH 7.2) containing 50 mg/mL of lysozyme and
incubated for 1 h at 37uC. The spores were then washed
sequentially with distilled water, 0.05% SDS and three washes
with distilled water. The concentration of the viable spores was
determined by plating serial dilutions of the heat-treated samples
(60 min at 65uC) on LB plates. Spores were killed by autoclaving
at 121uC for at least 30 minutes.
Purification of recombinant p24
Recombinant p24 with an N-terminal histidine tag was purified
by affinity chromatography [unpublished data]. Briefly, E. coli
BL21 (DE3) cells (Invitrogen) were transformed with the
recombinant pET28b/p24 vector and used as the host for protein
expression after induction with 0.5 mM isopropyl-b-D-thiogalac-
topyranoside (IPTG) (Fermentas Life Tecnologies). The cells were
harvested 2 h post-induction by centrifugation, and the cell pellet
was suspended in buffer A (500 mM NaCl, 100 mM Tris-HCl,
1 mM PMSF, pH 8). The cells were lysed and centrifuged, and
the supernatant was clarified with a 0.45 mm mesh membrane
filter. Protein purification was carried out in a HisTrapTM HP
column (GE Healthcare Bio-Sciences Corp) by immobilized metal
affinity chromatography (IMAC) using an AKTA model FPLC
equipment (Healthcare Bio-Sciences Corp). The column was
washed with buffer A and the bound proteins were eluted using a
linear gradient with buffer B (500 mM NaCl, 100 mM Tris-HCl,
1 M Imidazole, pH 8). The peak fractions were dialyzed against
phosphate buffered saline (PBS) and concentrated using a
membrane filter with a 5 kDa cutoff value (Millipore). The protein
concentration was determined using a Bicinchoninic acid (BCA)
assay (Pierce) and the purity was monitored by SDS-PAGE.
Endotoxin level was equal or lower than 2.0 EU/mg of protein,
after its removal by successive washing steps with 1% Triton X-
114 [21].
Adsorption of proteins to spores
Protein adsorption to spores was carried out as previously
described [7]. Briefly, 2 mg of the recombinant purified p24
protein was added to a suspension containing 26109 spores in
0.2 mL of 1X PBS at pH 4, pH 7 or pH 10. The pH was adjusted
using HCl or NaOH. After 1 h of incubation at room
temperature, the spores were washed 2 times with 1X PBS by
centrifugation, and the pellets resuspended in the same buffer. The
amount of protein adsorbed to the spore coat, after the washing
steps, was quantified by dot-blot assay, as previously described
[22].
Mice and immunization regimens
Pathogen-free BALB/c, C57BL/6, MyD88 and TLR2 deficient
mice (C57BL/6 genetic background) at 6–8 weeks of age were
used for these studies. The animals were supplied by the Isogenic
Mouse Breeding Facilities of the Departments of Parasitology and
Immunology, Institute of Biomedical Sciences of the University of
Sa˜o Paulo (USP). Groups of five animals were submitted to an
immunization regimen comprising three doses administered via
the subcutaneous route on days 0, 14, 21. Mice were inoculated
with 700 ng of p24 alone, 700 ng of p24 in combination with
15 mg of Alum, 10 mg of p24 admixed with 1 mg of LT1, 26109 of
live B. subtilis spores adsorbed with 700 ng of p24 and 700 ng of
p24 mixed with 26109 of live or heat-killed spores. This mixture
was performed using 0.2 mL of 16 PBS at pH 10 and the
inoculation of mice was done right after the mixing, in order to
avoid any adsorption of the antigen to the spore surface. The
control groups received sterile PBS. Sera samples were collected
one day before each dose to analyze the antibody production.
Serum antibody detection
Antigen-specific antibodies in serum were analyzed by ELISA,
according to previously described procedures, with minor mod-
ifications [23,24]. Maxisorp plates (Nunc) were coated with
purified p24 protein (300 ng/well) diluted in PBS at pH 7.5 and
were incubated overnight at 4uC. The wells were washed three
times with PBS containing 0.05% Tween 20 (PBS-T) and were
blocked with 1% BSA in PBS for 2 h at 37uC. Serum samples
were serially diluted in blocking solution and incubated for 1 h at
37uC. Antibody levels were detected using horseradish peroxidase-
conjugated rabbit anti-mouse IgG, IgG1, IgG2a or IgG2c (Sigma
and Southern Biotech) for 1 h at 37uC. The color was developed
with the addition of ortho-phenylenediamine (OPD) substrate, and
the absorbance was measured at 492 nm.
Determination of CD4+ and CD8+T cell response
Two weeks after the last immunization, the mice were
euthanized, and the spleens were removed. The cell suspension
was obtained by macerating the spleen and treating the cells with
ammonium chloride and potassium (ACK buffer) to lyse the
erythrocytes. The spleen cells were stimulated for 16 h, at 37uC in
a 5% CO2 atmosphere and in the presence of brefeldin-A, with a
synthetic peptide (GenScript) corresponding to the CD4
(AMQMLKETINEEAAE) or CD8 (AMQMLKETI) T cell-
specific epitope of the HIV gag p24 protein, at a final
concentration of 5 mg/mL or 10 mg/mL, respectively. Following
incubation, cells were washed twice in PBS supplemented with 2%
of fetal bovine serum (FBS) and surface stained with anti-CD8
fluorescein isothiocyanate (FITC) and anti-CD4 Cy (BD BioSci-
Adjuvanticity of Bacillus subtilis Spores
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ences). Next, the cells were washed, fixed with paraformaldehyde
and permeabilized with saponin, and then intracellularly stained
for IL-4 or IFN-c phycoerythrin (PE) (BD BioSciences). FACS
analysis was performed on a BD FACSCalibur flow cytometer,
and the results were analyzed using FlowJo (Tree Star) software.
Bone-marrow-derived dendritic cells (BMDC) generation
Murine BMDCs were prepared as formerly described [25,26]
with minor modifications. Briefly, cells were collected from the
femoral bone of 6–12 week old C57BL/6 mice, were seeded into
non-treated cell culture plates and were cultured at 37uC and 5%
CO2 for 8–9 days in 10 mL of conditioned medium (RPMI-1640
supplemented with 10% heat-inactivated FBS, 100 U/mL of
Penicillin/Streptomycin, 4% non-essential amino acids, 90 mM b-
mercaptoethanol, 30 ng/mL murine GM-CSF and 10 ng/mL of
IL-4). On day 4, the supernatant was gently removed and replaced
with the same volume of pre-warmed conditioned medium. On
day 8, BMDCs were collect from the plate and washed once with
PBS.
Effect of B. subtilis spores on APCs in vitro
BMDCs were treated with PBS, 1 mg of LT1 and live or heat-
killed spores at a multiplicity of infection (MOI) of 10000. Twenty-
four hours later, the culture supernatants were collected, and the
cytokine levels were determined by ELISA using commercially
available sets OptEIA (BD Pharmingen). For flow cytometry
analysis, cells were collected and stained for 30 min at 4uC with
PE-labeled anti-CD11c, APC-labeled anti-CD40 and FITC-
labeled anti-MHC I and anti MHC II (BD Pharmingen). After
three washing steps, the cells were resuspended in PBS and the
samples were analyzed by first gating on CD11c positive cells and
then examined for expression of costimulatory molecules. Sixty
thousand events were acquired using a FACSCaliburTM (Becton
Dickinson) flow cytometer, and the data were analyzed using the
FlowJo software (Tree Star).
Monitoring damages in immunized mice
One day after the third dose, the animals were bled via the
retro-orbital plexus for the individual determination of lactate
dehydrogenase (LDH) and C-reactive protein (CRP) levels, using
analytical kits as recommended by the supplier (Laborclin and
Bioclin, Brazil, respectively). Complete blood cell counts were also
taken at this time. Whole blood samples were used to evaluate five
hematological parameters: white blood cells (WBC), monocytes
(MON), lymphocytes (LYM), neutrophils (NEU) and eosinophils
(EOS). WBC counts were carried out using a Neubauer chamber
and MON, LYM, NEU and EOS counts were performed using a
phase contrast microscope (Eclipse E200 model, Nikon) [27].
Statistical analyses
Statistical significance (p,0.05) was determined using two-way
ANOVA followed by the Bonferroni posttest. The mean
fluorescence intensity (MFI) data were analyzed by Student’s t
test. Analyses were conducted using GRAPHPAD PRISM 5
software and were expressed as the means 6 standard error of
mean (s.e.m.).
Results
The adjuvant effects of co-administered B. subtilis spores
are independent of host genetic background
B. subtilis spores have been used as particulate adjuvants for
enhancing immune responses based in two main approaches: co-
administration with soluble antigens or with proteins adsorbed
onto the spore surface [7,8]. To verify which strategy would confer
stronger adjuvant effects, we used the recombinant HIV-1 gag p24
protein, which has been used in several anti-HIV vaccine
strategies as a model antigen [23,24,28]. BALB/c and C57BL/6
mice were immunized with 700 ng of p24 protein alone, co-
administered with or adsorbed onto 26109 B. subtilis spores.
Although we had successfully adsorbed the protein onto the spore
surface and obtained the maximum adsorption value (700 ng of
Figure 1. Adsorption of the p24 protein to spores of the B.
subtilis WW02 strain. (A) Evaluation of protein adsorption to spores at
different pHs. Spores (26109) were suspended in PBS buffer at pH 4,
pH 7 or pH 10, mixed with purified p24 protein (2 mg) and kept for 1 h
at room temperature. The samples were centrifuged, washed twice with
PBS and the spore coat proteins were extracted and submitted to
electrophoresis in SDS-PAGE at 15%. The control lane (Con) represents
spore samples without incubation with the protein and the control lane
(Pr) shows 2 mg of purified p24. Image is representative of four
independent experiments. (B) Detection of protein released from spores
after adsorption. Spores adsorbed with p24 (PBS at pH 4) were
resuspended in PBS at pH 4, pH 7 or pH 10 and incubated for different
times. At indicated time points (15, 30, 45, and 60 min) samples were
centrifuged and the supernatants and pellet (spores) were loaded onto
15% SDS-PAGE gel. (C) Determination of the saturation curve of p24
protein adsorption to B. subtilis spores. Increasing amounts of protein
(0.5 to 4 mg) were added to B. subtilis spores (26109) following the
procedure described before. The amount of protein adsorbed to the
spores coat was quantified by dot-blot assay.
doi:10.1371/journal.pone.0087454.g001
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p24) at pH 4 (Fig. 1), the immunization experiments demonstrated
no significant adjuvant effect either in BALB/c or C57BL/6 mice
(Fig. 2A, 2B). However, co-administration of the protein with
spores promoted a significant increase in the antibody titers
against p24 in both mice strains, demonstrating that the adjuvant
effects are not affected by the genetic background of the host.
Additionally, we observed that antibody responses against the
spores were generated in all experimental groups with no
difference between the two strategies (Fig. 2C, 2D). This leads us
to believe that the protein adsorption strategy does not favor the
adjuvanticity of spores regarding the humoral immune responses.
Live and heat-killed spores can be used as parenteral
adjuvants
We tested whether the co-administration of heat-killed spores
could enhance antigen-specific antibody responses. The results
indicate that both live and heat-killed spores induce similar serum
anti-p24 IgG levels in both mice strains (Fig. 3A, 3B). A similar
behavior was also observed after determining the antigen-specific
IgG subclass responses. After the third dose, administration of p24
alone induced an elevated IgG2a/IgG1 and IgG2c/IgG1 ratios,
indicating a more Th1-polarized response. On the other hand,
mice immunized with p24 co-administered with spores reduced to
IgG2a/IgG1 ratio, ranging from 0.7 to 2.59, and IgG1/IgG2c
ratio, ranging from 0.6 to 3.6 (Fig. 3C, 3D). The reduction of
IgG2a/IgG1 and IgG2c/IgG1 ratios was also observed in mice
immunized with p24 in combination with Alum, an adjuvant
associated with the induction of Th2 responses [29]. In order to
investigate if the balanced distribution of IgG1 and IgG2 isotypes
in mice immunized with p24 co-administered with spores was
indicative of generation of both Th1 and Th2 responses, the
activation of CD4+ and CD8+ T cell responses were measured in
Figure 2. Evaluation of antibody responses following subcutaneous immunization with p24 protein adsorbed or mixed with
spores. Mouse groups (n = 5) were immunized (three doses on days 0, 14 and 28) with 26109 spores (%), 700 ng of p24 only (#), 700 ng of p24 in
combination with 26109 spores (&) or 700 ng of p24 adsorbed at 26109 spores (N). Levels of anti-p24 (A and B) and anti-spores (C and D) specific
IgG antibodies were detected in serum samples at 13, 27 and 41 days after immunization in BALB/c and C57 BL/6 mice. The results are presented as
the mean 6 s.e.m. of three independent experiments, and the values obtained from PBS immunized mice were subtracted from each group. *** p,
0.001 when compared with mice immunized with p24 only.
doi:10.1371/journal.pone.0087454.g002
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the spleen cells harvested two weeks after the last immunization
dose. Co-administration of live or heat-killed spores induced a
stronger activation of p24-specific CD4+ T cells, which were
capable of producing IL-4 or IFN-c, than the mice immunized
with p24 only (Fig. 4A, 4B). Mice immunized with 700 ng of p24
co-administered with spores also showed higher p24 specific CD8+
T cell responses than the mice immunized with p24 only (Fig. 4C).
Considering that mice immunized with p24 in combination with
Alum did not elicit a T cell response higher than mice immunized
with p24 only (data not shown), we used, as a control, 10 mg of p24
admixed with 1 mg of heat-labile toxin type 1 (LT1) produced by
enterotoxigenic Escherichia coli previously characterized by the
significant humoral and cellular adjuvant effects [30].
Safety evaluation of B. subtilis as parenteral adjuvant
To develop a new vaccine adjuvant for human or veterinary
use, it is important to evaluate the safety of the vaccine in
preclinical studies. To evaluate the safety of B. subtilis spores as
vaccine adjuvant, we examined the hematological profile (white
blood, monocytes, lymphocytes, neutrophils and eosinophils) of
mice immunized with three doses of live or heat-killed spores. As
indicated in Table 1, no evidence of hematologic disturbances was
observed after the subcutaneous administration of the spores. We
also evaluated the physical changes (hair loss and local inflamma-
tion), the histologic alterations of the inguinal lymph nodes and the
non-specific biochemical markers of inflammatory reactions. No
differences were found between the control group (immunized
Figure 3. Humoral responses after subcutaneous immunization with p24 protein mixed with live or heat-killed spores. Detection of
anti-p24 specific IgG antibodies in serum samples of immunized BALB/c (A) and C57 BL/6 mice (B). Mouse groups (n = 5) were immunized (three
doses on days 0, 14 and 28) with viable spores (n), heat-killed spores (HkSp) (e), p24 protein (#), p24 protein in combination with Alum (&), p24
protein in combination with spores (N) or p24 protein in combination with heat-killed spores (m). *** p,0.001 when compared with group
immunized with p24 only or with each other. Specific IgG subclasses elicited in BALB/c (C) and C57BL/6 (D) mice after complete immunization
regimen. The IgG2a/IgG1 or IgG2c/IgG1 ratios are indicated at the top of the figure. * p,0.05 or *** p,0.001. All the results are presented as the
mean 6 s.e.m. of three independent experiments, and the values obtained from PBS immunized mice were subtracted from each group.
doi:10.1371/journal.pone.0087454.g003
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subcutaneously with PBS) and the group immunized with spores
(data not shown). These data indicate that B. subtilis spores, in the
complete immunization regimen via the subcutaneous route, are
safe for use as a promising adjuvant.
Maturation of dendritic cells by B. subtilis WW02 spores
Surface expression of co-stimulatory molecules and cytokine
secretion are some of the features observed during activation of
antigen presenting cells, such as dendritic cell (DC), a key step in
the generation of an adaptive immune response. A previous report
demonstrated that dead B. subtilis spores can enhance the
expression of MHC-II molecules and the secretion of IL-12 by
dendritic cells [9]. In this study, BMDCs were treated with live or
heat-killed spores of the B. subtilis WW02 strain to determine if
spores would induce the maturation of dendritic cells by
enhancing the expression of the surface molecules and the
Figure 4. Intracellular cell staining and flow cytometry analysis of p24-specific CD4+ and CD8+ T cells. BALB/c mice were immunized
(three doses on days 0, 14 and 28) with p24 protein (700 ng), p24 (10 mg) admixed with LT1 (1 mg), p24 (700 ng) admixed with spores (26109) or p24
(700 ng) admixed with heat-killed spores (26109). Spleen cells were collected two weeks after the last dose, and the detection of IL-4 producing p24-
specific CD4+ T cells (A) and IFN-c producing p24-specific CD4+ (B) and CD8+ T cells (C) was carried out after stimulation with MHC class I or II
restricted p24 peptide and cell surface staining for CD8 (FITC), CD4 (Cy) and intracellular staining for IL-4 or IFN-c (PE). The percentage of each
population is indicated in the upper right corners and the frequencies in all groups in the absence of stimulus were below 0.70% (data not shown).
Measurements were performed in duplicate for each individual sample, and the data are representative of two independent experiments.
doi:10.1371/journal.pone.0087454.g004
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secretion of cytokines. Levels of IL-12, TNF-a and IL-1b detected
in supernatants collected from DC cultured in vitro were
significantly increased after treatment with spores, and the live
spores induced a higher secretion of IL-12 than the heat-killed
spores (Fig. 5A). FACS analysis of dendritic cells treated with
spores revealed increased surface expression of MHC I, MHC II
and CD40 molecules, although live spores were more effective in
inducing MHC II surface expression (Fig. 5B, 5C). These results
indicate that spores can induce DC activation and production of
pro-inflammatory cytokines.
The innate immunity and the adjuvant effects of B.
subtilis spores
DC can express several pattern recognition receptors including
the toll-like receptors, which can recognize different molecular
patterns that are common in microorganisms. Signals generated
from various toll-like receptors determine the nature of immune
responses, and the ligands of toll-like receptors are potent
stimulators of the adaptive immune system [31]. We evaluated
whether live and heat-killed B. subtilis spores interact with toll-like
receptors and can synergistically potentiate vaccine-induced
responses. First, we analyzed if the signaling pathway that is
dependent on the adapter protein MyD88 is related to the
adjuvant effect of the spores during the humoral response to p24.
Wild type and MyD88 knockout C57BL/6 mice received 700 ng
of p24 protein alone or co-administered with 26109 of live or
heat-killed spores. In mice immunized with protein p24 only, the
humoral immune response was not affected by MyD88 inactiva-
tion. However, MyD88 knockout mice did not show enhancement
of the p24-specific antibody response after co-administration with
either live or heat-killed B. subtilis spores (Fig. 6A). Because the
MyD88 signaling pathway is involved in the adjuvant effect of
spores, we decided to determine which TLR plays a role in this
process. Considering that B. subtilis vegetative cells and spores can
stimulate the in vitro expression of TLR2 by dendritic cells [32], we
immunized TLR2 knockout C57BL/6 mice with different vaccine
formulations. TLR2 knockout mice were not able to elicit a strong
systemic antibody response to the antigen with regard to the wild
type mouse strain when the protein was co-administered with B.
subtilis spores (Fig. 6B). These data indicate that the spores interact
with DCs via TLR2 and promote maturation of these cells,
leading to enhanced adaptive immune responses.
Discussion
The limited immunogenicity of most purified vaccine antigens
has raised interest for new adjuvants with enhanced efficacy and
safety. Previous studies have shown that B. subtilis spores can
enhance the immune response against protein antigens and
represent a potential candidate for a novel particulate adjuvant.
Nonetheless, a better understanding of the adjuvant activity of B.
subtilis spores is crucial to design more effective vaccine formula-
tions. The results described in this study clarify the mechanisms
underlying the induction of the humoral and cellular immune
responses to live and heat-killed spores that are subcutaneously
administered to mice.
Initially, we compared the effectiveness of two previously
reported approaches in which spores were used as vaccine
adjuvants [7,8]. The first approach consisted of the adsorption
of proteins onto the spore surface, and the second approach
consisted of the co-administration of the spores with the antigen.
Our results demonstrated that, in the two tested mouse strains, co-
administration of spores result in a better adjuvant effect on the
induced antigen-specific antibody response when compared with
the results generated in mice immunized with spores in which the
antigen was adsorbed on the spore surface. Because the anti-spore
antibody responses were similar in both immunization approaches,
the lower adjuvanticity recorded with antigen-adsorbed spores
could not be attributed to any impairment of the immunization
procedure. Although previous studies have shown that the
adsorption of proteins onto the spore coat is an effective strategy
to increase the antibody response against soluble antigens
following mucosal administration [7], we could not confirm this
effect using a parenteral administration route.
The genetic background of the mouse strain may affect the Th
profile of the induced immune responses in animals submitted to
an immunization regimen. C57BL/6 mice characteristically show
a Th1 immune response pattern with high production of INF-c by
T cells, whereas BALB/c mice develop a Th2 biased immune
response with high production of IL-4 [33]. Previous studies have
shown that B. subtilis spores can induce a balanced Th1 and Th2
response pattern [8]. In this study, we further confirmed the same
immune response pattern induced in both C57BL/6 and BALB/c
mouse strains. In addition, specific antibody production and
activation of antigen specific IL-4 producing CD4+ T cells and
IFN-c producing CD4+ T and CD8+ T cells were detected after
immunization with B. subtilis spores. Collectively, these results
strongly suggest that spores can elicit both humoral and cellular
immune responses which are independent of the host genetic
background when administered via parenteral route.
Alum was more efficient to increase the humoral responses
against p24 than spores, but failed to increase cellular immune
responses to the same antigen. LT1, on the other hand, performed
better than spores to induce CD4+ and CD8+ T cell responses, but
only at experimental conditions in which the antigen was used at a
significantly higher concentration. Live and heat-killed spores were
equally effective in inducing an increase in the humoral and
cellular response against p24, using a lower dose of antigen.
Besides the fact that heat-killed spores are as efficient as live spores
is a feature that would further facilitate the handling and storage of
this adjuvant.
Effective stimulation of T cells requires appropriate signaling
provided by matured dendritic cells, such as increased expression
of costimulatory molecules and secretion of cytokines, and the
Table 1. Hematological analyses of mice immunized with B.
subtilis sporesa.
Hematological BALB/c C57BL/6
parametersb PBS Sp HkSp PBS Sp HkSp
WBC 55631 58613 40612 61611 50617 58611
MON 3.863 1.361.1 1.561.4 1.860.9 1.661.3 0.860.4
LYM 54617 4169 2866.3 4669.3 3569.1 47610
NEU 1062.2 1564.4 7.161.8 7.363.1 1368.6 9.761.1
EOS 0.960.6 0.660.1 3.163.2 4.661.7 0.260.3 1.160.7
aFive mice per immunization group were bled 1 day following the final dose.
bBlood samples were processed to determine white blood cells (WBC),
monocytes (MON), lymphocytes (LYM), neutrophils (NEU) and eosinophils (EOS).
All the counts are given in 102 cells/ml.
Data are expressed as the mean 6 SD of individual measurements. Differences
among groups were not observed after ANOVA and Bonferroni’s Multiple
Comparison test. The results in this table represent one of two independent
experiments.
Sp: B. subtilis WW02 spores; HkSp: Heat-killed B. subtilis WW02 spores.
doi:10.1371/journal.pone.0087454.t001
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Figure 5. Maturation of dendritic cells after stimulation with B. subtilis spores. (A) Induction of pro-inflammatory cytokines after stimulation
with spores. BMDCs from C57BL/6 mice were treated with PBS (control group), LT1 and live or heat-killed spores at a MOI of 10.000. Supernatants
were collected after 24 h, and the IL-1b, IL12p70 and TNF-a concentrations were quantified by ELISA. (B) Expression of surface molecules by CD11c+
cells following exposure to spores. BMDCs were treated as described above and the surface expression levels of CD40, MHC-I and MHC-II were
measured by flow cytometry. Gray-filled histograms represent samples incubated with PBS and open histograms represent samples incubated with
spores. The MFI for both conditions is shown in the upper left in each histogram. (C) Graphical comparison of the expression of CD40, MHC-I and
MHC-II. Data represent mean values 6 s.e.m. of two independent experiments. *p,0.05, **p,0.01 or *** p,0.001 when compared with control
group or with each other. Sp: B. subtilis WW02 spores; HkSp: Heat-killed B. subtilis WW02 spores.
doi:10.1371/journal.pone.0087454.g005
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presentation of antigenic peptides bound to MHC molecules [6].
Our in vitro studies showed that live and heat-killed spores can
induce the maturation of dendritic cells, increasing the expression
of pro-inflammatory cytokines and MHC-I, MHC-II and CD40
molecules, although live spores were more effective than heat-
killed spores in inducing MHC-II surface expression and IL-12
secretion. Thus, such increased activation of dendritic cells by live
B. subtilis spores may be attributed to spore germination, either in
the culture medium or inside the cells following phagocytosis, as
previously demonstrated to occur [32].
DCs can respond to foreign organisms, initiating an intracellular
signaling pathway mediated by the TLR receptor that leads to the
production of pro-inflammatory cytokines and costimulatory
molecules that link innate and adaptive immunity. MyD88
knockout mice failed to enhance the p24 specific antibody
response in the presence of the spores, indicating that the signaling
pathway operates through the MyD88 signaling pathway to exert
the adjuvant effects in mice. Although the MyD88-dependent
pathway is utilized by most of TLRs, our results provide evidence
that adjuvanticity of B. subtilis spores results from recognition by
Toll-like receptor 2 because the adjuvant effect disappeared in
immunized TLR2 knockout mice.
Safety issues represent a major challenge in the search of new
adjuvants for animals and humans. Our results indicate that B.
subtilis spores can be administered via parenteral routes without
causing measurable side effects and, therefore, can be regarded as
safe for parenteral inoculation. No alterations in biochemical and
hematological parameters were detected following immunization
with the spores, indicating that the subcutaneous administration of
a high amount of spores does not pose major safety concern issue.
In summary, our study significantly advances the current
understanding of the mechanisms involved with the adjuvanticity
of B. subtilis spores. We demonstrated that parenteral co-
administration of live and killed spores can safely induce an
increase of the specific antibody and T cell response to HIV gag
p24 antigen in both BALB/c and C57BL/6 murine models. In
addition, the spores stimulated DCs to express pro-inflammatory
cytokines and costimulatory molecules via TLR2 and MyD88
signaling pathway.
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